Carestream’s new Native Lesion Management Module for Vue PACS receives FDA clearance

Carestream received U.S. Food and Drug Administration (FDA) clearance for its new lesion management module, which is a native oncology follow-up application that can be added to the company’s Vue PACS image viewing workstation. Carestream will demonstrate the tools on a Vue PACS workstation at the upcoming Radiological Society of North America (RSNA) tradeshow.

Carestream’s new lesion management tools (see video demo) provide semi-automatic tracking and segmentation of lesions and can be used with other vendors’ PACS systems. Each measurement generates an anatomical bookmark within the exam, which radiologists can navigate and diagnose.

“The proven volumetric registration combined with the new lesion management feature in our Vue PACS synchronizes views from current and prior exams, allowing radiologists to measure and compare lesions, as well as tumors, nodules and other anatomical structures,” said Cristine Kao, Carestream’s Global Marketing Manager for Healthcare Information Solutions. “The comparison results are displayed with each exam and can be embedded into the final diagnostic report for other clinicians for review.”

Making these tools available as an optional native PACS module can eliminate the cost of dedicated workstations. The lesion management application can also equip radiologists with the ability to generate comprehensive oncology imaging reports in accordance with industry standards such as Response Evaluation Criteria in Solid Tumors (RECIST).

For more information on Carestream’s medical imaging and healthcare IT solutions, visitwww.carestream.com.